Can IL-2 keep HIV patients healthier without antiretrovirals?

NCT ID NCT00120185

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether interleukin-2 (IL-2) can help maintain CD4 cell counts in people with HIV who have not yet started antiretroviral therapy. 130 participants with CD4 counts between 300 and 500 will receive IL-2 injections. The goal is to see if IL-2 can delay the need for standard HIV medications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Interleukin-2 (IL-2)

What this could lead to

If successful, this could show that IL-2 helps delay the need for antiretroviral therapy in early HIV infection.

What could go wrong

This is a small, early-phase trial with only 130 participants. IL-2 may not prevent CD4 decline, and side effects are possible. Results may not apply to all HIV patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service des Maladies Infectieuses

    Paris, 75010, France